Mesothelioma Vesicles Carry Subtype-Specific microRNA Signatures
Researchers found extracellular vesicles from two pleural mesothelioma subtypes carry distinct microRNA cargoes that reprogram nearby fibroblasts.
Updated on Nov. 1, 2026 in Cancer
High-throughput profiling showed that extracellular vesicles from epithelioid and non-epithelioid pleural mesothelioma carry distinct microRNA cargoes, differing from non-malignant controls. Oncogenic miRNAs were upregulated and tumour-suppressive miRNAs downregulated in these vesicles.
Why it matters
The findings suggest microRNA content in extracellular vesicles could help distinguish pleural mesothelioma subtypes and inform treatment decisions. They also point to vesicle-driven signalling as a possible therapeutic avenue.
The study used high-throughput profiling of pleural mesothelioma-derived extracellular vesicles compared against non-malignant controls, showing upregulated oncogenic and downregulated tumour-suppressive miRNAs. Whether these markers perform reliably in patients has not yet been established.
The details
Researchers isolated extracellular vesicles from epithelioid and non-epithelioid pleural mesothelioma and treated fibroblasts with them. The treated fibroblasts shifted predominantly toward an inflammatory cancer-associated fibroblast-like phenotype, with increased IL-6/8, MMP-1/3 and other markers, while epithelioid and non-epithelioid vesicles differently affected p-EZH2 levels.
Health Landscape
The work extends research on cancer-associated fibroblasts reshaping the tumour microenvironment by identifying extracellular vesicle microRNA cargo as one driver of that reprogramming. It adds to a growing body of mesothelioma research seeking subtype-specific markers beyond traditional histology.
Any future biomarker test based on these microRNAs would need clinical validation before it could guide treatment choices for mesothelioma patients. Until then, current diagnosis and subtyping practices remain unchanged.
The takeaway
Subtype-specific signals in tumour-derived vesicles may eventually sharpen how clinicians classify mesothelioma. For now, the work remains preclinical and points to hypotheses that need testing in patients.
Further reading
Explore more research on Cancer and how tumour biology is being studied across subtypes.
Source note: This article includes information reported by Nature.
